Better Evidence for Selecting Transplant Fluids

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 808 participants.

Also called NCT03829488

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 808 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03829488
  • ANZCTR ACTRN12617000358347
Other papers using this trial's data
  • Balanced crystalloid solution versus saline in deceased donor kidney transplantation (BEST-Fluids): a pragmatic, double-blind, randomised, controlled trial Lancet (London, England), 2023-07-08 DOI, PubMed 37343576 PubMed links an erratum for this paper. Erratum: PMID 37393103

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, New Zealand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03829488. Randomized; quadruple masking; primary purpose treatment. Start 2018-01-26 (actual); primary completion 2021-07-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Better Evidence for Selecting Transplant Fluids
Acronym
BEST-Fluids
Condition
End Stage Kidney Disease
Condition
Delayed Graft Function
Condition
Kidney Transplant; Complications
Intervention (Drug)
Plasma-Lyte 148 (approx. pH 7.4) IV Infusion
Intervention (Drug)
0.9% SODIUM CHLORIDE 9g/L injection BP
Lead sponsor
The University of Queensland (class: other)
Collaborator
Australian Government Department of Health and Ageing (class: other government)
Collaborator
Health Research Council, New Zealand (class: other)
Collaborator
Baxter Healthcare Corporation (class: industry)

Record details

Record id
cardio:ct-nct03829488
Content hash
d515c1cdbbaae532a207726a08642420393422bc1b902d435db68fcde2af5c55